Punti chiave
- 1Iron accumulates silently with every transfusion; interrupted chelation causes organ damage before symptoms appear.
- 2Chelation monitoring costs (ferritin, cardiac/liver MRI) do not fall with the medicine price — budget for them separately.
- 3National patient associations are consistently the fastest route to entitlement knowledge and interim support.
- 4Adherence review mattered as much as price: chelator side effects already reduce compliance, so supervision after the switch was essential.
Panoramica del caso
- Profilo del paziente
- Composite profile — 14-year-old with transfusion-dependent beta thalassaemia
- Paese
- Italy, family originally from South Asia
- Condizione
- Transfusion-dependent thalassaemia with iron overload
- Farmaco
- Deferasirox oral iron chelation
Costo occidentale
~$50,400 per year
Alternativa di riferimento
~$820 per year reference
Impatto
~$49,580 per year
In questa pagina
1Why chelation is not optional
Transfusion-dependent thalassaemia requires regular red cell transfusions, often every few weeks, for life. Each transfusion delivers iron that the body has no efficient way to excrete.
Accumulated iron deposits in the heart, liver and endocrine organs. Untreated iron overload is a leading cause of death in transfusion-dependent thalassaemia, primarily through cardiac complications.
Iron chelation therapy removes that excess iron. It is therefore not supportive care in any optional sense — it is the treatment that determines long-term survival.
2Where the cost sits
The transfusions themselves were covered by the health system. The oral chelator was the component that fell outside routine coverage during a period when the family's entitlement was being reassessed.
| Component | Branded basis | Generic reference | Reduction |
|---|---|---|---|
| Deferasirox 500 mg daily | ~$50,400 | ~$820 | 98% |
| Alternative: deferiprone | ~$34,200 | ~$580 | 98% |
| Ferritin and MRI monitoring | ~$1,100 | ~$1,100 | unchanged |
| Transfusions | System covered | System covered | n/a |
3How the haematology team handled it
The centre treated it as a treatment-continuity issue and involved a patient association early.
- 1Confirmed that chelation must continue without interruption.
- 2Verified generic deferasirox manufacturers with recognised approvals.
- 3Kept the monitoring schedule completely unchanged — ferritin regularly, cardiac and liver MRI annually.
- 4Involved a national thalassaemia association, which provided interim support and advocacy on entitlement.
- 5Recorded product and batch details at each dispensing.
- 6Reviewed adherence carefully, since chelators can cause gastrointestinal side effects that reduce compliance.
4Outcome
Ferritin trends and cardiac MRI at twelve months were consistent with adequate chelation, confirming the therapy was working. Entitlement was subsequently restored.
The family's most valuable action was contacting the national patient association. Disease-specific associations frequently hold detailed knowledge of entitlement rules, appeals processes and interim support that is very hard to find independently.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
Showing figures without a story leaves the real lesson out: these cases are about adherence that became possible again, monitoring that started up again, and rationing that stopped — not simply about a cheaper invoice.
Discuss any change of medicine, dose or brand with a licensed clinician before acting on anything on this page.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
Cosa mostra il dataset Jivan
- 33.1×
- divario medio di prezzo Haematology
- 50%
- degli ancore supera 10×
- 89×
- divario più ampio documentato
Across our Haematology anchors, 10 referenced molecules average a 33.1× price gap, 50% of them are at least 10× cheaper in India, and the widest documented comparison is Hydroxyurea Sickle Cell at 89×. Haematology chelation anchors sit in the deepest-discount band of the entire catalog, because the patient base is concentrated where the pricing ceiling binds hardest.
Calcolato in tempo reale da 10 anchors
Domande frequenti
No. Iron accumulates continuously with every transfusion and causes organ damage silently. Interruption should only ever occur on haematologist instruction, usually for a specific clinical reason.
Generic deferasirox is approved on bioequivalence grounds in regulated markets and is widely used. Effectiveness is directly verifiable through ferritin trends and iron MRI.
Through regular serum ferritin measurement and periodic MRI assessment of cardiac and liver iron. This monitoring is essential and should never be reduced to save money.
Fonti e approfondimenti
Ogni affermazione sopra è riconducibile a una fonte primaria pubblica. Citiamo enti regolatori e organismi sanitari pubblici, non venditori commerciali.
- 1WHO Model List of Essential MedicinesWorld Health Organization
- 2Generic and Hybrid MedicinesEuropean Medicines Agency
- 3MedlinePlus Drug InformationU.S. National Library of Medicine
- 4Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)U.S. Food & Drug Administration
Come è nato questo articolo
Scritto e ricercato
Pricing Research Editor, Jivan Editorial TeamRevisionato editorialmente
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Avviso medico importante
Consulta sempre un medico prima di cambiare farmaco, dose o marca. Jivan offre informazioni educative e sui prezzi e non sostituisce la diagnosi né le cure d'urgenza.